Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04354064Recruiting

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Role: collaborator

NCT01511458Completed

Non-invasive Chromosomal Examination of Trisomy Study

Role: lead

NCT01256606Completed

Prenatal Test for Fetal Aneuploidy Detection

Role: lead

All 3 trials loaded